XMT-1536

August 13, 2020August 13, 2020

XMT-1536 on FDA Fast Track for Platinum-resistant, Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has given fast track designation to Mersana Therapeutics’ XMT-1536 as a possible treatment for women with platinum-resistant high-grade serous ovarian cancer who received up to three prior lines ... Read more

April 15, 2020April 15, 2020

Antibody-drug Conjugate XMT-1536 Shows Promise for Ovarian Cancer in Phase 1 Trial

News

Treatment with XMT-1536 appears to be safe, with promising responses shown in heavily pretreated patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma in a Phase 1 clinical ... Read more

November 3, 2017

FDA OKs Mersana’s XMT-1536 for Clinical Investigation in Ovarian, Other Solid Tumors

News

Mersana Therapeutics is advancing its antibody-drug conjugate XMT-1536 into clinical development for ovarian and other tumor types, after the U.S. Food and Drug Administration cleared the company’s investigational new drug (IND) ... Read more